Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- readableassertion label "describe the assertion concisely (e.g. tylenol treats pain in adults patients)" assertion.
- object label "search for the disease it treats" assertion.
- cohortAgeLabel label "describe the life stage or age of the cohort (e.g. Adults)" assertion.
- cohort label "the study cohort" assertion.
- subject label "search for the indicated drug" assertion.
- publication label "add the URL of a publication supporting this association (doi, PubMed...)" assertion.
- cohortAgeMax label "describe the maximum age of the cohort (e.g. 80)" assertion.
- hasPhenotype label "provide additional phenotypes for the cohort" assertion.
- cohortAgeMin label "describe the minimum age of the cohort (e.g. 7)" assertion.
- assertion label "Defining a drug indication with its context (BioLink model)" assertion.
- association label "Spironolactone, USP is contraindicated for patients with anuria, acute renal insufficiency, significant impairment of renal excretory function, hyperkalemia, Addison's disease or other conditions associated with hyperkalemia, and with concomitant use of eplerenone." assertion.
- context label "adults" assertion.
- association label "TCAs can serve as first-line or augmenting drugs for neuropathic pain, headache, migraine, gastrointestinal syndromes, fibromyalgia, pelvic pain, insomnia, and psychiatric conditions other than depression." assertion.
- context label "adults" assertion.
- association label "Antidepressants (eg, tricyclic antidepressants [TCAs], SNRIs, SSRIs) are often prescribed off label to manage cataplexy " assertion.
- context label "adults" assertion.
- association label "Antidepressants (eg, tricyclic antidepressants [TCAs], SNRIs, SSRIs) are often prescribed off label to manage cataplexy " assertion.
- context label "adults" assertion.
- association label "Antidepressants (eg, tricyclic antidepressants [TCAs], SNRIs, SSRIs) are often prescribed off label to manage cataplexy " assertion.
- context label "adults" assertion.
- association label "Antidepressants (eg, tricyclic antidepressants [TCAs], SNRIs, SSRIs) are often prescribed off label to manage cataplexy " assertion.
- association label "Antidepressants (eg, tricyclic antidepressants [TCAs], SNRIs, SSRIs) are often prescribed off label to manage cataplexy " assertion.
- context label "adults" assertion.
- association label "In patients with Li-NDI, off label therapy with amiloride can be useful." assertion.
- context label "adults" assertion.
- context label "adults" assertion.
- association label "TCAs have been used to treat chronic low back pain for decades and have been repeatedly shown to be more effective than placebo in reducing pain severity" assertion.
- HP_0003419 label "Low Back pain" assertion.
- HP_0003419 label "Low back pain" assertion.
- context label "adults" assertion.
- association label "TCAs have been used to treat chronic low back pain for decades and have been repeatedly shown to be more effective than placebo in reducing pain severity" assertion.
- association label "Patients with irritable bowel syndrome have long been known to benefit from TCAs; the number needed to treat for symptomatic benefit over placebo is 3.5" assertion.
- context label "adults" assertion.
- association label "Information extracted from Table 2." assertion.
- context label "adults" assertion.
- context label "adults" assertion.
- association label "TCAs can serve as first-line or augmenting drugs for neuropathic pain, headache, migraine, gastrointestinal syndromes, fibromyalgia, pelvic pain, insomnia, and psychiatric conditions other than depression." assertion.
- context label "Adults" assertion.
- association label "Antidepressants, particularly TCAs and SNRIs, have also found their application in relieving pain related with fibromyalgia. Table 2 contains off-label drugs prescribed." assertion.
- association label "Antidepressants, particularly TCAs and SNRIs, have also found their application in relieving pain related with fibromyalgia" assertion.
- context label "Adults" assertion.
- association label "Antidepressants, particularly TCAs and SNRIs, have also found their application in relieving pain related with fibromyalgia" assertion.
- context label "Adults" assertion.
- MONDO_0024317 label "chronic pain syndrome" assertion.
- MONDO_0024317 label "chronic pain syndrome" assertion.
- MONDO_0024317 label "chronic pain syndrome" assertion.
- MONDO_0024317 label "Chronic pain syndrome" assertion.
- MONDO_0024317 label "Chronic pain syndrome" assertion.
- MONDO_0024317 label "Chronic pain syndrome" assertion.
- MONDO_0024317 label "Chronic pain syndrome" assertion.
- MONDO_0024317 label "Chronic pain syndrome" assertion.
- MONDO_0024317 label "Chronic pain syndrome" assertion.
- association label "NaN" assertion.
- context label "Adults" assertion.
- association label "The observed efficacy of antidepressants as treatment for bulimia nervosa led to trials to evaluate their effect on binge eating disorder. Antidepressants that have shown promising results include bupropion, duloxetine, escitalopram, fluvoxamine, fluoxetine, imipramine, sertraline and venlafaxine" assertion.
- context label "Adults" assertion.
- MONDO_0005582 label "binge eating disorder" assertion.
- MONDO_0005582 label "binge eating disorder" assertion.
- MONDO_0005582 label "binge eating disorder" assertion.
- MONDO_0005582 label "binge eating disorder" assertion.
- MONDO_0005582 label "binge eating disorder" assertion.
- MONDO_0005582 label "binge eating disorder" assertion.
- MONDO_0005582 label "binge eating disorder" assertion.
- context label "Adults" assertion.
- association label "The observed efficacy of antidepressants as treatment for bulimia nervosa led to trials to evaluate their effect on binge eating disorder. Antidepressants that have shown promising results include bupropion, duloxetine, escitalopram, fluvoxamine, fluoxetine, imipramine, sertraline and venlafaxine" assertion.
- association label "The observed efficacy of antidepressants as treatment for bulimia nervosa led to trials to evaluate their effect on binge eating disorder. Antidepressants that have shown promising results include bupropion, duloxetine, escitalopram, fluvoxamine, fluoxetine, imipramine, sertraline and venlafaxine" assertion.
- context label "Adults" assertion.
- context label "Adults" assertion.
- association label "SSRIs including paroxetine, fluoxetine and escitalopram have been found as effective treatment for patients with premature ejaculation (Arafa and Shamloul, 2007). Premature ejaculation is also treated with clomipramine and sertraline (Balon, 1996; McMahon, 1998), as well as with dapoxetine, a member of the SSRI family, which is however not used to treat depression (Andersson et al., 2006)" assertion.
- MONDO_0001780 label "Premature ejaculation (disease)" assertion.
- MONDO_0001780 label "Premature ejaculation (disease)" assertion.
- MONDO_0001780 label "Premature ejaculation (disease)" assertion.
- MONDO_0001780 label "Premature ejaculation (disease)" assertion.
- MONDO_0001780 label "Premature ejaculation (disease)" assertion.
- MONDO_0001780 label "premature ejaculation (disorder)" assertion.
- MONDO_0001780 label "premature ejaculation (disorder)" assertion.
- association label "SSRIs including paroxetine, fluoxetine and escitalopram have been found as effective treatment for patients with premature ejaculation (Arafa and Shamloul, 2007). Premature ejaculation is also treated with clomipramine and sertraline (Balon, 1996; McMahon, 1998), as well as with dapoxetine, a member of the SSRI family, which is however not used to treat depression (Andersson et al., 2006)" assertion.
- context label "Adults" assertion.
- context label "Adults" assertion.
- association label "SSRIs including paroxetine, fluoxetine and escitalopram have been found as effective treatment for patients with premature ejaculation (Arafa and Shamloul, 2007). Premature ejaculation is also treated with clomipramine and sertraline (Balon, 1996; McMahon, 1998), as well as with dapoxetine, a member of the SSRI family, which is however not used to treat depression (Andersson et al., 2006)" assertion.
- association label "Although antidepressants are not the first-line prophylactic strategy for patients with migraine, several clinical trials have proven their effectiveness in the treatment of migraine and related headache disorders (Koch and Jurgens, 2009). Especially TCAs: amitriptyline (Couch and Hassanein, 1979; Jackson et al., 2010; Kalita et al., 2013) and nortriptyline (Holroyd et al., 2001; Jackson et al., 2010) have the best evidence for use in migraine prevention. When amitriptyline is not tolerated by patients, treatment is continued with nortriptyline (Burch, 2019)." assertion.
- context label "Adults" assertion.
- association label "Drugs from all five classes of antidepressants have been investigated for use as smoking cessation aids (Shoaib and Buhidma, 2018). The second generation TCA nortriptyline is regarded as the most promising alternative to bupropion. This antidepressant mainly inhibits noradrenaline and serotonin transporters (Kripke, 2005). Antidepressants of the SSRI category are not effective, however, suggesting that serotonin does not play the main role in smoking addiction (Hughes et al., 2014)." assertion.
- context label "Adults" assertion.
- NCIT_C17427 label "smoking cessation" assertion.
- context label "Adults" assertion.
- association label "Among TCAs, doxepin (sinequan) appears to be best suited for managing insomnia in healthy adults. Doxepin works as a selective antagonist to H(1) receptors, which promote the initiation and maintenance of sleep (Owen, 2009) (Table 2). Ultra-low doses of this drug (< 6 mg per day) significantly improve and sustain both maintenance and duration of sleep (Rojas-Fernandez and Chen, 2014; Weber et al., 2010). Another frequently prescribed TCA is amitriptyline, which as a long-term option is found to be effective for patients with ongoing sleep problems (Everitt et al., 2014; Pagel and Parnes, 2001)." assertion.
- association label "Among TCAs, doxepin (sinequan) appears to be best suited for managing insomnia in healthy adults. Doxepin works as a selective antagonist to H(1) receptors, which promote the initiation and maintenance of sleep (Owen, 2009) (Table 2 contains information on trazodone and mirtazapine). Ultra-low doses of this drug (< 6 mg per day) significantly improve and sustain both maintenance and duration of sleep (Rojas-Fernandez and Chen, 2014; Weber et al., 2010). Another frequently prescribed TCA is amitriptyline, which as a long-term option is found to be effective for patients with ongoing sleep problems (Everitt et al., 2014; Pagel and Parnes, 2001)." assertion.
- context label "Adults" assertion.
- context label "Adults" assertion.
- association label "The SGA olanzapine is considered the most appropriate, followed by quetiapine and aripiprazole. Although off-label prescription of SGAs represents a common clinical practice in accordance with a worldwide trend, the use of long-acting injection formulations was considered inappropriate by 69% of psychiatrists in our sample. Attitudes on off-label use of Aripiprazole in the treatment of BPD: Highly inappropriate = 44 (21.8%); Innapropriate = 38 (18.8%); Doubt = 74 (36.6%); Appropriate = 43 (21.3%); Highly appropriate = 3 (1.5%) " assertion.
- context label "Adults" assertion.
- association label "Attitudes on off-label use of Clozapine in the treatment of BPD: Highly inappropriate = 115 (56.9%); Innapropriate = 32 (15.8%); Doubt = 42 (20.9%); Appropriate = 13 (6.4%); Highly appropriate = 0 (0%) " assertion.
- context label "Adults" assertion.
- association label "Attitudes on off-label use of Paliperidone in the treatment of BPD: Highly inappropriate = 81 (40.1%); Innapropriate = 32 (15.8%); Doubt = 66 (32.7%); Appropriate = 20 (9.9%); Highly appropriate = 3 (1.5%) " assertion.
- context label "Adults" assertion.
- association label "Attitudes on off-label use of Risperidone in the treatment of BPD: Highly inappropriate = 51 (25.2%); Innapropriate = 31 (15.3%); Doubt = 90 (44.6%); Appropriate = 28 (13.9%); Highly appropriate = 2 (1.0%) " assertion.
- context label "Adults" assertion.
- association label "Hence, it is possible that its popularity in special populations is due to the fact that the unpleasant or unwanted effects of addiction substances are somehow soothed by quetiapine. Currently, quetiapine is tested in substance use disorders, showing some promise, but it is likely to be misused in certain contexts" assertion.
- context label "Adults" assertion.